Skip to main content
Yingna Liao on Muck Rack

Yingna Liao

As seen in: Nature, Cell Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yingna

Contact Yingna, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer

|
By Rong Tang, Liquan Jin, Chen Chen, Yingna Liao, Dingru Li, Yangyi Li, Yueyue Chen, Yuan Liu, Qiong Du, Zeyin Rong, Yubin Lei, Zijian Wu, Zhen Tan, Yufeng Wang, Haoyu Wang, Jin Xu, Wei Wang, Xianjun Yu, Jiaoshun Chen
| Cell Press Verified
Results From a total of 3,103 real-world patients who underwent surgical resection (referred to as the FUSCC-surgPDAC cohort), 547 tumor samples were available in sufficient quantity for RNA extraction and subsequent analyses. These samples were further evaluated for RNA integrity and then subjected to snRNA-seq procedures.
Open in Who Shared Issue with article?

The emerging role of disulfidptosis in metabolic synergistic death and cancer immunotherapy

|
By Zheng Wu, Rong Tang, Jin Xu, Yufeng Wang, Liquan Jin, Yingna Liao, Dingru Li, Cheng Zu, Chengkai Yang, Xianjun Yu
| Nature Verified
Abstract Disulfidptosis is an emerging form of regulated cell death (RCD) that is mechanistically distinct from, yet closely interconnected with, classical cell death modalities such as apoptosis, ferroptosis, and cuproptosis. It is typically triggered in cells with high expression of solute carrier family 7 member 11 (SLC7A11, also known as xCT) under glucose-deprived conditions.
Open in Who Shared Issue with article?

Metabolic characterization of the tumor microenvironment orchestrates therapeutic strategies and clinical outcomes in pancreatic cancer

|
By Rong Tang, Yangyi Li, Cong Zhou, CHEN CHEN, Yueyue Chen, Yuan Liu, Qiong Du, Yubin Lei, Zijian Wu, Jin Xu, Wei Wang, Xiaoyu Yin, Xianjun Yu, Chunbin Zhu, Liquan Jin, Yingna Liao, Chenghao Shao
| Nature Verified
Abstract Metabolic reprogramming and immunosuppressive tumor microenvironment (TME) are hallmark features driving pancreatic ductal adenocarcinoma (PDAC) progression. Despite the therapeutic potential of targeting immunometabolism, effective strategies remain scarce in clinical practice, likely due to cell-specific metabolic heterogeneity within PDAC TME.
Open in Who Shared Issue with article?
See all 3 articles